Physicians' Academy for Cardiovascular Education

Several biomarkers identified as predictors of outcomes in hypertrophic cardiomyopathy

Blood-based biomarkers for the prediction of hypertrophic cardiomyopathy prognosis: a systematic review and meta-analysis

Literature - Jansen M, Algül S, Bosman LP, et al. - ESC Heart Fail. 2022 Jul 17. doi: 10.1002/ehf2.14073

Introduction and methods


Although the overall mortality of patients with hypertrophic cardiomyopathy (HCM) is low, the clinical severity of this disease is highly variable [1]. Therefore, better risk stratification is desirable, and perhaps biomarkers can meet this need.

Aim of the study

The researchers aimed to review the current knowledge of the prognostic utility of serum and plasma biomarkers in HCM and assess the available evidence, focusing on outcomes involving malignant ventricular arrhythmia (MVA), left ventricular outflow tract (LVOT) obstruction, and HF.


In this systematic review and meta-analysis, 26 unique cohort studies assessing 42 biomarkers in total were included. Risk of bias was assessed with the Quality in Prognostic Studies tool. Two independent authors assessed the study quality.


The primary endpoints were HF, MVA, and LVOT obstruction. Additional composite endpoints were surrogate endpoints for HCM progression (including AF , unexplained syncope, non-sustained ventricular tachycardia, ICD implantation, thromboembolic stroke, and all-cause mortality) and components of the co-primary endpoints.

Main results


In pooled analyses, several biomarkers were identified as predictors of HCM outcomes. The authors stress that further research is required to establish the prognostic utility of these biomarkers for specific outcomes and to evaluate their value when they are incorporated in current risk stratification models.


Show references

Find this article online at ESC Heart Fail.

Share this page with your colleagues and friends: